Allylestrenol
Allylestrenol
|
| Systematic (IUPAC) name |
| (17β)-17-(prop-2-en-1-yl)estr-4-en-17-ol |
| Clinical data |
| Pregnancy cat. |
Used in threatened miscarriage and RPL |
| Legal status |
? |
| Identifiers |
| CAS number |
432-60-0 Y |
| ATC code |
G03DC01 |
| PubChem |
CID 235905 |
| DrugBank |
DB01431 |
| ChemSpider |
205855 Y |
| UNII |
I47VB5DZ8O Y |
| KEGG |
D01374 Y |
| ChEMBL |
CHEMBL1445549 N |
| Synonyms |
17α-Allylestr-4-en-17β-ol |
| Chemical data |
| Formula |
C21H32O |
| Mol. mass |
300.48 g/mol |
| SMILES |
eMolecules & PubChem |
-
InChI=1S/C21H32O/c1-3-12-21(22)14-11-19-18-9-8-15-6-4-5-7-16(15)17(18)10-13-20(19,21)2/h3,6,16-19,22H,1,4-5,7-14H2,2H3/t16-,17+,18+,19-,20-,21-/m0/s1 Y
Key:ATXHVCQZZJYMCF-XUDSTZEESA-N Y
|
N(what is this?) (verify)
|
Allylestrenol (BAN/INN), also known as allyloestrenol and allyl estrenol, is a synthetic progestogen used to prevent threatened miscarriage, recurrent pregnancy loss and premature labor.[1][2] In men, it has also been studied as a treatment for benign prostatic hyperplasia, with encouraging results.[3][4]
Allylestrenol is sold under several trade names, including Gestin, Turinal, Gestanin, Gestanol or Gestanon, Maintaine, Orageston, and Profar. It is currently not marketed in the United States, United Kingdom, or Canada, but as of 2011[update], is extensively used in Japan, Russia, India, and much of Southeast Asia.[1]
References
- ^ a b Sweetman, Sean C., ed (2009). "Sex hormones and their modulators". Martindale: the complete drug reference (36th ed.). London: Pharmaceutical Press. p. 2082. ISBN 978-0-85369-840-1.
- ^ Cortés-Prieto J, Bosch AO, Rocha JA (1980). "Allylestrenol: three years of experience with Gestanon in threatened abortion and premature labor". Clinical Therapeutics 3 (3): 200–8. PMID 7459930.
- ^ Fukuoka H, Ishibashi Y, Shiba T, Tuchiya F, Sakanishi S (July 1993). "[Clinical study of allylestrenol (Perselin) on patients with prostatic hypertrophy]" (in Japanese). Hinyokika Kiyo. Acta Urologica Japonica 39 (7): 679–83. PMID 7689782.
- ^ Noguchi K, Takeda M, Hosaka M, Kubota Y (May 2002). "[Clinical effects of allylestrenol on patients with benign prostatic hyperplasia (BPH) evaluated with criteria for treatment efficacy in BPH]" (in Japanese). Hinyokika Kiyo. Acta Urologica Japonica 48 (5): 269–73. PMID 12094708.
External links